Precision Medicine

At AACR 2026, CREATE Medicines debuts its RetroT platform, an all-RNA system for stable gene delivery that avoids viral vectors and reshapes cell therapy.

Byondis presents two novel ADC platforms at AACR 2026, aiming to solve drug resistance and offer hope for patients unresponsive to immunotherapy.

With $36M secured, Orthogon Therapeutics is advancing a first-in-class oral drug for BK virus, offering a new lifeline for transplant patients.

For over a decade, Wake Radiology has backed the Komen Race for the Cure, funding research and expanding access to life-saving breast cancer screenings.

New data reveals Mapi Pharma's long-acting GA Depot stabilizes disability in both relapsing and progressive MS, poised for a 2027 European launch.

Patients, doctors, and researchers unite for a grueling ride across Iceland, raising funds and hope for a future free from multiple myeloma.

A new oral drug candidate for lupus and RA emerges as Totus Medicines uses its AI platform to rapidly develop a first-in-class inhibitor for the elusive IRF5 protein.

A novel drug for a debilitating stomach disorder is set for a major reveal, offering hope to millions with limited and often risky treatment options.

An FDA-approved system lets surgeons see residual cancer in real-time during lumpectomies, offering new hope for avoiding the dreaded second surgery.

San Diego's Blacksmith Medicines will present promising data on its FEN1 inhibitor, a new drug targeting a notoriously difficult class of enzymes.

A Boston biotech says its new AI platform moves beyond correlation to find the true biological causes of disease, promising a new era for medicine.

A Chinese biotech has won a key approval for a novel antibody designed to fight deadly leukemias with enhanced safety, marking a new frontier in cancer care.

Promising early safety data for a novel drug, KM-023, brings a potential first-ever targeted treatment for the devastating Olmsted syndrome a step closer.

A parent-led company gains a U.S. patent for a diazoxide formulation, offering new hope for managing behavioral symptoms in Prader-Willi syndrome.

RIMAN's parent company is partnering with Harvard to test a new ingredient on 'organ-on-a-chip' tech, a move set to redefine evidence in skincare.

Win a VIP trip to meet P!NK while supporting vital cancer research. A new fundraising model emerges as public funding for life-saving science dwindles.

A son's concern for his mother sparks an investment in a startup using AI to combat the hidden dangers of chronic dehydration affecting millions.

With its lead depression drug nearing Phase 3, AtaiBeckley faces investors to tackle the regulatory and commercial hurdles of psychedelic medicine.

Harrow partners with specialist LogiCare3PL for U.S. distribution, highlighting an industry shift towards agile, high-touch logistics for faster market access.

Renaissance Pharma's Daretabart gains FDA support for high-risk neuroblastoma, accelerating its journey to patients and offering new hope against this rare disease.